<DOC>
	<DOCNO>NCT03025516</DOCNO>
	<brief_summary>This prospective , multicentre study conduct evaluate diagnostic accuracy two TB breath-based technology independently manufacturer . Assay error failure rate device operational characteristic also assess study . Participants enrol study line FIND sample banking activity . Results index test use make clinical decision . Participation study alter standard care .</brief_summary>
	<brief_title>Performance Evaluation TB Breath- Cough-testing Platforms</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<criteria>Symptoms suggest pulmonary TB , i.e . persistent cough ( generally &gt; 3 week per local definition TB suspect ) least one finding list : 1 . Persistent cough 2 . Fever 3 . Malaise 4 . Recent weight loss 5 . Night sweat 6 . Contact w/ active case 7 . Hemoptysis 8 . Chest pain 9 . Loss appetite 10 . Other [ specify ] Provision inform consent sample collection , bank HIV breathbased assay test Production adequate quantity sputum ( sputum induction whenever possible ) Adult age ( &gt; 18 year old ) Participants receive antituberculosis medication , include fluoroquinolone aminoglycosides 60 day prior enrolment . Participants ONLY extrapulmonary disease exclude . Participants complete followup clear final diagnosis judge difficult ( e.g . resident elsewhere move ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>